HIV/AIDS Update - Tentative approval for Lamivudine and Tenofovir DF Fixed Dose Combination Tablets, 300 mg/300 mg

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: HIV/AIDS Update - Tentative approval for Lamivudine and Tenofovir DF Fixed Dose Combination Tablets, 300 mg/300 mg

You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

On March 4, 2011, the Food and Drug Administration (FDA) granted tentative approval for lamivudine and tenofovir DF Fixed Dose Combination Tablets, 300 mg/300 mg indicated in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients 12 years old and older.

The application was reviewed under the expedited review provisions of the President’s Emergency Plan for AIDS Relief (PEPFAR), this product is manufactured by Cipla Limited of Mumbai, India.

"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for purchase outside the United States under the PEPFAR program.

As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.

You can find a complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan on the FDA web site.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration


Manage your FDA Subscriptions:

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux